Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Review of the current approaches to the assessment of the drug innovative potential worldwide

https://doi.org/10.17749/2070-4909.2017.10.3.066-074

Full Text:

Abstract

A set of criteria for assessing the innovative potential of drugs (therapeutic value) have been developed and are widely used elsewhere. These approaches allow the state (the payer) to assess the clinical significance of a new medical product and make an educated decision on the reimbursement, cost and priority at the stage of registration. In the Russian Federation though, such criteria and methods are not sufficiently developed. This review describes the principle approaches to assessing the drug innovative potential in countries outside Russia. 

About the Authors

N. Z. Musina
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia; Centre of Expertise and quality control of Russian Ministry of Health care
Russian Federation

Musina Nuriya Zagitovna – PhD, Lecturer at the Department of Pharmacology, Faculty of Pharmacy, the First Moscow Medical Sechenov University; Senior researcher at the Healthcare Finance Center of the Research Financial Institute of the Ministry of Finance of the Russian Federation; Chief of the development and communications department, the Center of Healthcare Quality Assessment and Control, the Ministry of Health of the Russian Federation.

Corresponding author Address: ul. Trubetskaya, 8-2, Moscow, Russia, 119991. (Musina N. Z.).



V. K. Fedyaeva
The Russian Presidential Academy of National Economy and Public Administration; Research Institute of Finance, Ministry of Finance of the Russian Federation
Russian Federation
Fedyaeva Vlada Konstantinovna – Researcher at the Center for Healthcare Technology Assessment of the Russian Presidential Academy of National Economy and Public Administration, Senior laboratory assistant at the Healthcare Finance Center of the Research Financial Institute of the Ministry of Finance of the Russian Federation


V. V. Omel’yanovskii
The Russian Presidential Academy of National Economy and Public Administration; Research Institute of Finance, Ministry of Finance of the Russian Federation
Russian Federation
Omelyanovskiy Vitaliy Vladimirovich – MD, Professor, Director of the Center for Healthcare Technology Assessment at the Institute of Applied Economic Research of RANEPA, Head of the Healthcare Finance Center of the Research Financial Institute of the Ministry of Finance of the Russian Federation


G. R. Khachatryan
The Russian Presidential Academy of National Economy and Public Administration; Research Institute of Finance, Ministry of Finance of the Russian Federation
Russian Federation
Khachatryan Georgii Rubenovich – MD, Researcher at the Laboratory for Healthcare Technology Assessment at the Institute of Applied Economic Research of the Russian Presidential Academy of National Economy and Public Administration, Junior researcher at the Center for Healthcare Funding of the Financial Scientific Research Institute at the Ministry of Finance of the Russian Federation


K. V. Gerasimova
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia; Centre of Expertise and quality control of Russian Ministry of Health care
Russian Federation
Gerasimova Kseniya Vladimirovna – PhD, Associate professor at High School of Healthcare administration at the Sechenov First Moscow state medical university. Deputy chief of the Department of Methodological Support for Comprehensive Healthcare Technology Assessment, Center of Healthcare Quality Assessment and Control, the Ministry of Health of Russian Federation


V. A. Lemeshko
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia; Centre of Expertise and quality control of Russian Ministry of Health care
Russian Federation
Lemeshko Valeriya Alexandrovna – Specialist at the Department of Methodological Support for Comprehensive Healthcare Technology Assessment, Center of Healthcare Quality Assessment and Control, The Ministry of Health of Russian Federation; Graduate student at the Department of Pharmacology, Faculty of Pharmacy, First Moscow Medical Sechenov University


K. P. Konchits
I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Konchits Sophya Pavlovna – Student at the Faculty of Pharmacy, the First Moscow Medical Sechenov University


References

1. Dremova N. B. Novaya apteka (in Russian). 2006; 8: 65-79.

2. Medynskii V. G. Innovative management: a textbook [Innovatsionnyi menedzhment: uchebnik (in Russian)]. Moscow. 2005; 293 s.

3. U.S. Food and Drug Administration: Drug Development and Review Definitions. URL: http://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/. Accessed: 25.07.2017.

4. AIFA, Model for ranking the therapeutic innovation for a new drug. URL: https://www.agenziafarmaco.it/allegati/intergral_document.pdf. Accessed: 28.07.2017.

5. The Use of Health Technology Assessments (HTA) to evaluate Medicines. Principles and guidance for implementation in different healthcare environments. EFPIA HTA Toolkit – Final. 04.02.2008.

6. Khachatryan G. R., A. V. Luneva A. V. Innovatsii v meditsine i opredelenie ikh tsennosti v zarubezhnykh stranakh: obzor literatury. Meditsinskie tekhnologii: otsenka i vybor. 2013; 4 (14): 23-29.

7. Senatore P., Chalmers M., Cyrus A. The New AIFA Algorithm For Assessing ‘Innovativeness’ Of New Products In Italy: So What? 18 August 2017. URL: http://cbpartners.com/blog/new-aifa-algorithm-assessinginnovativeness-new-products-italy.html. Accessed: 02.07.2017 .

8. Schlenkrich S. The Act on the Reform of the Market for Medicinal Products (AMNOG): A Question of Power?! Anchor Academic Publishing (aap_verlag), 2015.

9. Pricing & Reimbursement of drugs and HTA policies in France. National Authority for health (Haute Autorité de Santé), France march 2014. URL: https://www.has-sante.fr/portail/upload/docs/application/pdf/2014-03/pricing_reimbursement_of_drugs_and_hta_policies_in_france.pdf. Accessed: 01.07.2017.

10. Haute autorite de sante (HAS). URL: www.has-sante.fr. Accessed: 29.07.2017.

11. Pricing & Reimbursement of drugs and HTA policies in France. National Authority for health (Haute Autorité de Santé), France march 2014. URL: https://www.has-sante.fr/portail/upload/docs/application/pdf/2014-03/pricing_reimbursement_of_drugs_and_hta_policies_in_france.pdf. Accessed: 01.07.2017.

12. Paris V., Belloni A. Value in pharmaceutical pricing. 2013. URL: https://www.oecd.org/canada/Value-in-Pharmaceutical-PricingCanada.pdf Accessed: 29.07.2017.

13. World Health Organization et al. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. WHO Regional Office for Europe. 2015.

14. Omel’yanovskii V.V., Sura M. V., Sveshnikova N. D. Meditsinskie tekhnologii: otsenka i vybor (in Russian). 2011; 1 (3): 40

15. Paris V., Belloni A. Value in pharmaceutical pricing – country profile: Canada. 2014. URL: https://www.oecd.org/canada/Value-inPharmaceutical-Pricing-Canada.pdf . Accessed: 05.07.2017.

16. Market Access Challenges in 2017: Impacts of Japan’s Drug Pricing Policy Reforms. URL: https://decisionresourcesgroup.com/ drg-blog/market-access-challenges-2017-impacts-japans-drugpricing-policy-reforms/. Accessed: 05.07.2017

17. Hirashima S., T. Shigihara. JPMA Challenges Updates. JPMA meeting 2016.

18. Drug Pricing System in Japan. Ministry of Health, Labour, and welfare Insurance Bureau, 2016. URL: http://www.jpma.or.jp/english/ parj/pdf/17_supplement.pdf Accessed: 05.07.2017.

19. Hideyuki K., Toshiyuki H., Konomi I., Hisashi K., Noriatsu K. The Current Status of Sakigake Designation in Japan, PRIME in the European Union, and Breakthrough Therapy Designation in the United States. Therapeutic Innovation & Regulatory Science. 2016; 51 (1): 51-54.

20. Matsunaga Y. National Health Insurance (NHI) pricing formula in Japan. Improvement in methodology of pricing for new drugs and orphan drugs, 2014. URL: https://www.pmda.go.jp/files/000152228.pdf. Accessed: 06.07.2017.

21. Postanovlenie Pravitel’stva RF ot 15.04.2014 N 30 (red. ot 31.03.2017) «Ob utverzhdenii gosudarstvennoi programmy Rossiiskoi Federatsii «Razvitie farmatsevticheskoi i meditsinskoi promyshlennosti» na 2013-2020 gody». URL: http://www.pravo.gov.ru. Accessed: 29.07.2017.


For citation:


Musina N.Z., Fedyaeva V.K., Omel’yanovskii V.V., Khachatryan G.R., Gerasimova K.V., Lemeshko V.A., Konchits K.P. Review of the current approaches to the assessment of the drug innovative potential worldwide. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(3):66-74. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.3.066-074

Views: 218


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)